Filing Details
- Accession Number:
- 0001640455-21-000021
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-25 17:36:58
- Reporting Period:
- 2021-01-22
- Accepted Time:
- 2021-01-25 17:36:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1640455 | Jounce Therapeutics Inc. | JNCE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1604646 | M Hugh Cole | C/O Jounce Therapeutics, Inc. 780 Memorial Drive Cambridge MA 02139 | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-01-22 | 5,000 | $4.40 | 60,189 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-01-22 | 5,000 | $6.55 | 65,189 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-22 | 18,000 | $11.95 | 47,189 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-22 | 5,000 | $0.00 | 5,000 | $4.40 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-01-22 | 5,000 | $0.00 | 5,000 | $6.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 39,500 | 2029-02-01 | No | 4 | M | Direct | |
| 55,000 | 2030-02-03 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 22, 2020. The Reporting Person exercised no discretion with respect to these transactions.
- Represents the weighted average share price of an aggregate total of 18,000 shares sold in the price range of $11.66 to $12.24 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The option will vest quarterly in 16 equal installments following January 1, 2019.
- The option will vest quarterly in 16 equal installments following January 1, 2020.
Billionaire Hedge Funds
